PDUFA VII Talks To Begin With COVID-19, Other Familiar Issues To Consider
Executive Summary
US FDA staffing problems and patient engagement enhancements will be listed as priorities during reauthorization kick-off meeting.
You may also be interested in...
US FDA Oncology Center Wants Trial Datasets Flagged As Remote Or In-Person Assessments
Agency wants to use pandemic-interrupted clinical trials to gauge how decentralized approaches impacted study integrity and to inform prospective use of such designs post-COVID.
Pandemic Taking Its Toll On The US FDA’s Non-Pandemic Work, Alkermes CEO Says
Last year was not the greatest performance by the agency outside of COVID-19, Richard Pops tells BIO conference.
US FDA Drug Review Goals Should Be Faster In PDUFA VII, Industry Negotiators Propose
Sponsor representatives also want postmarketing discussions moved to earlier in the assessment cycle.